-
公开(公告)号：US11827689B2
公开(公告)日：2023-11-28
申请号：US17245123
申请日：2021-04-30
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
CPC classification number: C07K14/71 , A61K38/45 , C12N9/12 , C12Y207/1103 , A61K38/00 , C07K2319/30
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
-
公开(公告)号：US20220306724A1
公开(公告)日：2022-09-29
申请号：US17687934
申请日：2022-03-07
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Asya Grinberg , Erik M. Vogan
Abstract: In certain aspects, the present invention provides compositions and methods for modulating (promoting or inhibiting) growth of red blood cells or a tissue, such as bone, cartilage, muscle, fat, and/or neuronal tissue. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.
-
公开(公告)号：US20220017600A1
公开(公告)日：2022-01-20
申请号：US17184692
申请日：2021-02-25
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra , Kristian Pietras
IPC: C07K14/71
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
-
公开(公告)号：US20210388104A1
公开(公告)日：2021-12-16
申请号：US17140398
申请日：2021-01-04
Applicant: Acceleron Pharma Inc.
Inventor： Asya Grinberg , John Knopf , Robert S. Pearsall , Ravindra Kumar , Jasbir Seehra , Kristian Pietras
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.
-
公开(公告)号：US20210324089A1
公开(公告)日：2021-10-21
申请号：US17350608
申请日：2021-06-17
Applicant: Acceleron Pharma Inc.
Inventor： John Knopf , Jonathan Belk , Nathan J. Sharkey , Ravindra Kumar , Asya Grinberg , Dianne Sako , Roselyne Castonguay , Yossi Dagon
Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.
-
Patent Agency Ranking
公开(公告)号：US20210308206A1
公开(公告)日：2021-10-07
申请号：US17231981
申请日：2021-04-15
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
公开(公告)号：US20210300991A1
公开(公告)日：2021-09-30
申请号：US17205573
申请日：2021-03-18
Applicant: Acceleron Pharma Inc.
Inventor： Asya Grinberg , Roselyne Castonguay , Eric Werner , Ravindra Kumar
IPC: C07K14/705
Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (ENG) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders.
-
公开(公告)号：US11028145B2
公开(公告)日：2021-06-08
申请号：US16251935
申请日：2019-01-18
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay , Gang Li , Yossi Dagon , John Knopf
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK7 receptor and an extracellular domain of ActRIIB In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to improve metabolic parameters in a patient in need thereof. In certain aspects, these ALK7:ActRIIB heteromultimers are can be used to treat or prevent one or more kidney-associated disease or condition in a patient in need thereof.
-
公开(公告)号：US20210163569A1
公开(公告)日：2021-06-03
申请号：US16803230
申请日：2020-02-27
Applicant: Acceleron Pharma Inc.
Inventor： Ravindra Kumar , Asya Grinberg , Dianne Sako , Robert Scott Pearsall , Roselyne Castonguay
IPC: C07K14/705 , C07K14/71
Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of an ALK4 receptor and an extracellular domain of ActRIIB. In certain aspects, such soluble ALK4:ActRIIB complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, and/or cancerous cells. In certain aspects, such ALK4:ActRIIB complexes are can be used to improve muscle formation, bone formation, metabolic parameters, and disorders associated with these tissues, cellular networks, kidney, and endocrine systems.
-
90.发明授权公开(公告)号：US11000565B2
公开(公告)日：2021-05-11
申请号：US16390394
申请日：2019-04-22
Applicant: Acceleron Pharma Inc. , Adimab, LLC
Inventor： Ravindra Kumar , Jonathan Belk , Asya Grinberg , Dianne Sako , Roselyne Castonguay
Abstract: This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions.
-
-
-
-
-
-
-
-
-
Search Results
108
records
(took 0.022 seconds)
